Is viral clearance a hurdle to implementing continuous processing? This webinar shares virus spiking alternatives that may pave the way for effectively evaluating viral clearance by chromatography steps in a continuous process.
An important characteristic of an antibody is its Fc effector function, and antibodies are now being engineered for optimal binding to Fc receptors expressed on effector cells. It is crucial to evaluate the binding interaction of monoclonal antibodies (mAbs) with Fc receptors in the early phase of drug development to understand the potential biological activity of the product in vivo.
Where we see almost daily innovation in production technologies, many of the methods used for biosafety testing are decades old. This webinar explores how new methods can be used to accelerate biosafety testing today.
The relationship between physicochemical profile and biological activity — and how this relationship affects clinical performance — is key to making informed decisions, accelerating development, and reducing risk.
As part of the characterization package for biological products derived from cell lines, the manufacturing cell bank must be assessed for the presence of viral contamination. The development of the Blazar Rodent Panel allows biopharma to move away from traditional in vivo antibody production assays when characterizing cell banks of rodent origin used in the production of biologicals.
Did you know about the alternative rapid method for in vivo MAP/HAP/RAP testing? Download our tech note "Blazar™ Platform: Rodent Virus Panel from the BioReliance® Portfolio" to learn more about our novel degenerate PCR assay designed for the detection of a broad range of adventitious agents.